What Will Drive Korean Pharma's Next Decade Of Growth?
Ample Pipelines, Direct Global Entry May Be Key
A recent event in South Korea heard one prominent investor advise South Korean pharma firms to sharply increase their new drug R&D and seek direct entry into global markets, rather than pursuing licensing deals for growth
